Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 324

1.

First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy.

Valicenti RK, Pugh SL, Trabulsi EJ, Sartor O, Ko EC, Girvigian MR, Rosenthal SA, Shaves ME, Hoffman-Censits JH, Schallenkamp J, Sandler HM.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):695-701. doi: 10.1016/j.ijrobp.2017.11.024. Epub 2017 Nov 21.

PMID:
29413282
2.

Metastatic Prostate Cancer.

Sartor O, de Bono JS.

N Engl J Med. 2018 Feb 15;378(7):645-657. doi: 10.1056/NEJMra1701695. Epub 2018 Feb 7. Review. No abstract available.

PMID:
29412780
3.

Editorial Comment.

Qureshi ZP, Sartor O, Bennett CL.

Urology. 2017 Dec 27. pii: S0090-4295(17)31226-8. doi: 10.1016/j.urology.2017.08.068. [Epub ahead of print] No abstract available.

PMID:
29289356
4.

Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer.

Manogue C, Ledet E, Guddati AK, Lewis B, Sartor O.

Oncologist. 2017 Dec 19. pii: theoncologist.2017-0450. doi: 10.1634/theoncologist.2017-0450. [Epub ahead of print]

PMID:
29259071
5.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.

PMID:
29236593
6.

Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.

Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A Jr., Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ; U.S. Expanded Access Program Investigators.

Oncologist. 2018 Feb;23(2):193-202. doi: 10.1634/theoncologist.2017-0413. Epub 2017 Nov 28.

PMID:
29183960
7.

Adverse Event Reporting in Clinical Trials: Time to Include Duration as Well as Severity.

Sartor O.

Oncologist. 2018 Jan;23(1):1. doi: 10.1634/theoncologist.2017-0437. Epub 2017 Nov 20. No abstract available.

8.

Understanding the distressed prostate cancer patient: Role of personality.

Perry LM, Hoerger M, Silberstein J, Sartor O, Duberstein P.

Psychooncology. 2017 Nov 10. doi: 10.1002/pon.4579. [Epub ahead of print]

PMID:
29125208
9.

Abiraterone in Metastatic Prostate Cancer.

de Bono J, Eisenberger M, Sartor O.

N Engl J Med. 2017 Oct 26;377(17):1694-5. doi: 10.1056/NEJMc1711029. No abstract available.

10.

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.

Sartor O, Heinrich D, Mariados N, Méndez Vidal MJ, Keizman D, Thellenberg Karlsson C, Peer A, Procopio G, Frank SJ, Pulkkanen K, Rosenbaum E, Severi S, Trigo Perez JM, Wagner V, Li R, Nordquist LT.

Ann Oncol. 2017 Oct 1;28(10):2464-2471. doi: 10.1093/annonc/mdx331.

PMID:
28961839
11.

Editorial Comment.

Qureshi ZP, Sartor O, Bennett CL.

Urology. 2017 Nov;109:16-17. doi: 10.1016/j.urology.2017.04.063. Epub 2017 Sep 21. No abstract available.

PMID:
28941944
13.

Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.

Pezaro CJ, Omlin A, Mastris K; ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S.

Ann Oncol. 2017 Aug 1;28(8):1692-1694. doi: 10.1093/annonc/mdx312. No abstract available.

PMID:
28838209
14.

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, Fizazi K, Paruleker WR, Sandler HM, Sydes MR, Tombal B, Williams SG, Sweeney CJ; ICECaP Working Group.

J Clin Oncol. 2017 Sep 20;35(27):3097-3104. doi: 10.1200/JCO.2017.73.9987. Epub 2017 Aug 10.

PMID:
28796587
15.

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.

Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, Hjälm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O.

J Clin Oncol. 2017 Oct 1;35(28):3189-3197. doi: 10.1200/JCO.2016.72.1068. Epub 2017 Jul 28.

PMID:
28753384
16.

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S.

Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30516-X. doi: 10.1016/j.eururo.2017.06.021. [Epub ahead of print]

17.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A.

Eur Urol. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. Epub 2017 Jun 24.

18.

Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).

Sabol RA, Noxon V, Sartor O, Berger JR, Qureshi Z, Raisch DW, Norris LB, Yarnold PR, Georgantopoulos P, Hrushesky WJ, Bobolts L, Ray P, Lebby A, Kane RC, Bennett CL.

Cancer Med. 2017 Jul;6(7):1541-1551. doi: 10.1002/cam4.1098. Epub 2017 Jun 20.

19.

Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature.

Summers N, Vanderpuye-Orgle J, Reinhart M, Gallagher M, Sartor O.

Curr Med Res Opin. 2017 Nov;33(11):1995-2008. doi: 10.1080/03007995.2017.1341869. Epub 2017 Jul 10.

PMID:
28604117
20.

An Integrative Genomics Approach for Associating Genome-Wide Association Studies Information With Localized and Metastatic Prostate Cancer Phenotypes.

Hicks C, Ramani R, Sartor O, Bhalla R, Miele L, Dlamini Z, Gumede N.

Biomark Insights. 2017 Mar 16;12:1177271917695810. doi: 10.1177/1177271917695810. eCollection 2017.

21.

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.

Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Vogelzang NJ, Bruland Ø, Kobina S, Wilhelm S, Xu L, Shan M, Kattan MW, Parker C.

Ann Oncol. 2017 May 1;28(5):1090-1097. doi: 10.1093/annonc/mdx044.

22.

Advantages of a Truly Open-Access Data-Sharing Model.

Bertagnolli MM, Sartor O, Chabner BA, Rothenberg ML, Khozin S, Hugh-Jones C, Reese DM, Murphy MJ.

N Engl J Med. 2017 Mar 23;376(12):1178-1181. doi: 10.1056/NEJMsb1702054. No abstract available.

23.

Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.

Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CAF, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM.

Cancer. 2017 Jul 1;123(13):2489-2496. doi: 10.1002/cncr.30620. Epub 2017 Mar 21.

PMID:
28323339
24.

Navigating the evolving therapeutic landscape in advanced prostate cancer.

Crawford ED, Petrylak D, Sartor O.

Urol Oncol. 2017 May;35S:S1-S13. doi: 10.1016/j.urolonc.2017.01.020. Epub 2017 Mar 7. Review.

PMID:
28283376
25.

Editorial Comment.

Sartor O.

Urology. 2017 Apr;102:171-172. doi: 10.1016/j.urology.2016.10.045. Epub 2017 Mar 6. No abstract available.

PMID:
28279478
26.

Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, Kattan MW, Lin DW.

CA Cancer J Clin. 2017 May 6;67(3):245-253. doi: 10.3322/caac.21391. Epub 2017 Feb 21.

27.

Generic drugs in oncology - Authors' reply.

Bennett CL, Nagai S, Yang YT, Chen BK, Sartor O, Armitage JO.

Lancet Oncol. 2017 Feb;18(2):e64. doi: 10.1016/S1470-2045(17)30016-5. No abstract available.

PMID:
28214418
28.

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM; NRG Oncology RTOG.

N Engl J Med. 2017 Feb 2;376(5):417-428. doi: 10.1056/NEJMoa1607529.

29.

Acute Promyelocytic Leukemia After Treatment of Metastatic Castration-Resistant Prostate Cancer With Radium-223.

Odo U, Vasudevamurthy AK, Sartor O.

Clin Genitourin Cancer. 2017 Jun;15(3):e501-e502. doi: 10.1016/j.clgc.2016.12.028. Epub 2016 Dec 29. No abstract available.

PMID:
28111175
30.

Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.

Bennett CL, Sartor OA, Armitage JO, Kantarjian H.

Lancet Oncol. 2017 Jan;18(1):22-23. doi: 10.1016/S1470-2045(16)30653-2. No abstract available.

PMID:
28049571
31.

Prostate-specific Antigen Response and Eradication of Androgen Receptor Amplification with High-dose Testosterone in Prostate Cancer.

Schiff JP, Lewis BE, Ledet EM, Sartor O.

Eur Urol. 2017 Jun;71(6):997-998. doi: 10.1016/j.eururo.2016.12.010. Epub 2016 Dec 28. No abstract available.

PMID:
28040353
32.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.

McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL.

J Immunother Cancer. 2016 Dec 20;4:92. doi: 10.1186/s40425-016-0198-x. eCollection 2016.

33.

Beyond Just Androgen Deprivation Therapy: Novel Therapies Combined With Radiation.

Sartor O, Lewis B.

Semin Radiat Oncol. 2017 Jan;27(1):87-93. doi: 10.1016/j.semradonc.2016.08.003. Epub 2016 Aug 26. Review.

PMID:
27986215
34.

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.

Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, Sartor O, O'Sullivan JM, Coleman RE.

Eur J Cancer. 2017 Jan;71:1-6. doi: 10.1016/j.ejca.2016.10.020. Epub 2016 Dec 6.

35.

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.

Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, Mirtti T, Yu T, Bot BM, Shen L, Abdallah K, Norman T, Friend S, Stolovitzky G, Soule H, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Xie Y, Aittokallio T, Zhou FL, Costello JC; Prostate Cancer Challenge DREAM Community.

Lancet Oncol. 2017 Jan;18(1):132-142. doi: 10.1016/S1470-2045(16)30560-5. Epub 2016 Nov 16.

36.

Generic oncology drugs: are they all safe?

Yang YT, Nagai S, Chen BK, Qureshi ZP, Lebby AA, Kessler S, Georgantopoulos P, Raisch DW, Sartor O, Hermanson T, Kane RC, Hrushesky WJ, Riente JJ, Norris LB, Bobolts LR, Armitage JO, Bennett CL.

Lancet Oncol. 2016 Nov;17(11):e493-e501. doi: 10.1016/S1470-2045(16)30384-9. Review.

PMID:
27819247
37.

Prostate cancer: What is the optimal treatment sequence for mCRPC?

Sartor O.

Nat Rev Urol. 2016 Oct 31;13(11):639-640. doi: 10.1038/nrurol.2016.205. No abstract available.

PMID:
27797362
38.

A Whole Blood Assay for AR-V7 and ARv567es in Patients with Prostate Cancer.

Liu X, Ledet E, Li D, Dotiwala A, Steinberger A, Feibus A, Li J, Qi Y, Silberstein J, Lee B, Dong Y, Sartor O, Zhang H.

J Urol. 2016 Dec;196(6):1758-1763. doi: 10.1016/j.juro.2016.06.095. Epub 2016 Jul 20.

39.
40.

Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation.

Steinberger AE, Cotogno P, Ledet EM, Lewis B, Sartor O.

Clin Genitourin Cancer. 2017 Feb;15(1):e69-e71. doi: 10.1016/j.clgc.2016.09.001. Epub 2016 Sep 17. No abstract available.

PMID:
27726949
41.

Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance.

Zhan Y, Zhang G, Wang X, Qi Y, Bai S, Li D, Ma T, Sartor O, Flemington EK, Zhang H, Lee P, Dong Y.

Mol Cancer Res. 2017 Jan;15(1):59-68. doi: 10.1158/1541-7786.MCR-16-0236. Epub 2016 Sep 26.

42.

Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy.

McKay RR, Jacobus S, Fiorillo M, Ledet EM, Cotogna PM, Steinberger AE, Jacene HA, Sartor O, Taplin ME.

Clin Genitourin Cancer. 2017 Apr;15(2):e289-e298. doi: 10.1016/j.clgc.2016.08.015. Epub 2016 Aug 20.

PMID:
27651103
43.

Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.

Bennett CL, Berger JR, Sartor O, Carson KR, Hrushesky WJ, Georgantopoulos P, Raisch DW, Norris LB, Armitage JO.

Br J Haematol. 2018 Jan;180(2):301-304. doi: 10.1111/bjh.14322. Epub 2016 Sep 21. No abstract available.

PMID:
27649938
44.

Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.

Vogelzang NJ, Coleman RE, Michalski JM, Nilsson S, O'Sullivan JM, Parker C, Widmark A, Thuresson M, Xu L, Germino J, Sartor O.

Clin Genitourin Cancer. 2017 Feb;15(1):42-52.e8. doi: 10.1016/j.clgc.2016.07.027. Epub 2016 Aug 8.

45.

Estrogen-Mediated Activation of H875Y Androgen Receptor Mutation in a Prostate Cancer Patient.

Vasudevamurthy AK, Ledet E, Garvey C, Lewis BE, Sartor O.

Clin Genitourin Cancer. 2017 Feb;15(1):e111-e113. doi: 10.1016/j.clgc.2016.07.015. Epub 2016 Jul 22. No abstract available.

PMID:
27527401
46.

Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.

Qu F, Xie W, Nakabayashi M, Zhang H, Jeong SH, Wang X, Komura K, Sweeney CJ, Sartor O, Lee GM, Kantoff PW.

Clin Cancer Res. 2017 Feb 1;23(3):726-734. doi: 10.1158/1078-0432.CCR-16-1070. Epub 2016 Aug 3.

47.

Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.

Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D.

Eur Urol. 2016 Nov;70(5):875-883. doi: 10.1016/j.eururo.2016.06.002. Epub 2016 Jun 22.

48.

Racial variation in prostate needle biopsy templates directed anterior to the peripheral zone.

Feibus AH, Levy J, McCaslin IR, Doucet ME, Sholl AB, Moparty K, Thomas R, Sartor O, Silberstein JL.

Urol Oncol. 2016 Aug;34(8):336.e1-6. doi: 10.1016/j.urolonc.2016.03.017. Epub 2016 May 5.

PMID:
27155916
49.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B.

Ann Oncol. 2016 May 2. pii: mdw180. [Epub ahead of print] No abstract available.

PMID:
27141017
50.

Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy.

Feibus AH, Sartor O, Moparty K, Chagin K, Kattan MW, Ledet E, Levy J, Lee B, Thomas R, Silberstein JL.

J Urol. 2016 Oct;196(4):1053-60. doi: 10.1016/j.juro.2016.04.075. Epub 2016 Apr 29.

PMID:
27140073

Supplemental Content

Loading ...
Support Center